Holen Sie sich die Stockscreener-App
2.08
7.77%
0.15
Vorhandelsmarkt:
2.07
-0.01
-0.48%
Schlusskurs vom Vortag:
$1.93
Offen:
$1.95
24-Stunden-Volumen:
141.05K
Relative Volume:
0.61
Marktkapitalisierung:
$85.03M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-78.92M
KGV:
-1.0097
EPS:
-2.06
Netto-Cashflow:
$-72.87M
1W Leistung:
+16.85%
1M Leistung:
+22.35%
6M Leistung:
-44.09%
1J Leistung:
-27.27%
1-Tages-Spanne:
$1.9373
$2.10
1-Wochen-Bereich:
$1.785
$2.10
52-Wochen-Spanne:
$1.49
$6.06
Vigil Neuroscience Inc Stock (VIGL) Company Profile
Firmenname
Vigil Neuroscience Inc
Sektor
Branche
Telefon
857-254-4445
Adresse
100 FORGE ROAD, WATERTOWN
Vergleichen Sie VIGL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VIGL
Vigil Neuroscience Inc
|
2.08 | 85.03M | 0 | -78.92M | -72.87M | -2.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-04 | Eingeleitet | William Blair | Outperform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2022-09-16 | Eingeleitet | Wedbush | Outperform |
| 2022-08-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-01 | Eingeleitet | Guggenheim | Buy |
| 2022-02-01 | Eingeleitet | Jefferies | Buy |
| 2022-02-01 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-02-01 | Eingeleitet | Stifel | Buy |
Alle ansehen
Vigil Neuroscience Inc Aktie (VIGL) Neueste Nachrichten
Glimpse Group Inc (NASDAQ: VRAR) Down -21.05% This Year: What To Expect Next - Stocks Register
Them too in TREM2: Street keeping AD Vigil - BioWorld Online
Q4 Earnings Estimate for VIGL Issued By William Blair - MarketBeat
Q4 Earnings Forecast for VIGL Issued By William Blair - Defense World
Geode Capital Management LLC Raises Position in Ballard Power Systems Inc. (NASDAQ:BLDP) - Defense World
Geode Capital Management LLC Purchases 66,712 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - Defense World
Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones - GlobeNewswire
Vigil Neuroscience Lands $40M Sanofi Investment, FDA Signals Path for Accelerated Approval - StockTitan
Vigil Neuroscience stock hits 52-week low at $1.51 By Investing.com - Investing.com South Africa
Vigil Neuroscience stock hits 52-week low at $1.51 - Investing.com
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Sees Significant Decrease in Short Interest - MarketBeat
Vigil Neuroscience director Budd Haeberlein buys $20,520 in shares By Investing.com - Investing.com South Africa
Vigil Neuroscience director Budd Haeberlein buys $20,520 in shares - Investing.com India
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Director Haeberlein Samantha L. Budd Purchases 12,000 Shares - MarketBeat
VIGL stock touches 52-week low at $1.61 amid market challenges - Investing.com India
VIGL stock touches 52-week low at $1.61 amid market challenges By Investing.com - Investing.com South Africa
Vigil neuroscience CEO Ivana Magovcevic-Liebisch acquires $8,350 in stock - Investing.com India
Vigil neuroscience CEO Ivana Magovcevic-Liebisch acquires $8,350 in stock By Investing.com - Investing.com Australia
Vigil Neuroscience stock hits 52-week low at $2.07 - Investing.com India
Vigil Neuroscience (NASDAQ:VIGL) and ProKidney (NASDAQ:PROK) Head-To-Head Contrast - Defense World
Vigil Neuroscience initiated with an Outperform at William Blair - MSN
FY2024 Earnings Estimate for VIGL Issued By William Blair - MarketBeat
FY2024 Earnings Forecast for VIGL Issued By William Blair - Defense World
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL) - The Eastern Progress Online
William Blair Initiates Coverage on Vigil Neuroscience (NASDAQ:VIGL) - Defense World
Vigil neuroscience CEO Ivana Magovcevic-Liebisch buys $11,700 in stock By Investing.com - Investing.com Australia
Vigil neuroscience CEO Ivana Magovcevic-Liebisch buys $11,700 in stock - Investing.com
William Blair Initiates Coverage of Vigil Neuroscience (VIGL) with Outperform Recommendation - MSN
William Blair initiates Vigil Neuroscience with Outperform By Investing.com - Investing.com Nigeria
William Blair initiates Vigil Neuroscience with Outperform - Investing.com
Vigil Neuroscience shares rated Outperform by William Blair, advancing in Alzheimer's treatment - Investing.com Nigeria
Vigil Neuroscience: Down On A Competitor's Failure (NASDAQ:VIGL) - Seeking Alpha
Contrasting Vigil Neuroscience (NASDAQ:VIGL) and Surrozen (NASDAQ:SRZN) - Defense World
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Update - MarketBeat
JMP Securities Reiterates Market Outperform Rating for Vigil Neuroscience (NASDAQ:VIGL) - Defense World
Guggenheim maintains Buy on Vigil Neuroscience stock post-Alector trial By Investing.com - Investing.com Canada
Vigil Neuroscience stock hits 52-week low at $2.45 - Investing.com India
Vigil Neuroscience stock hits 52-week low at $2.45 By Investing.com - Investing.com UK
Guggenheim maintains Buy on Vigil Neuroscience stock post-Alector trial - Investing.com
Vigil Neuroscience's (VIGL) Market Outperform Rating Reiterated at JMP Securities - MarketBeat
Citadel Advisors LLC Adjusts Position in Vigil Neuroscience Inc - GuruFocus.com
Vigil Neuroscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Deep Track Capital, LP Increases Stake in Vigil Neuroscience Inc - GuruFocus.com
Vigil Neuroscience to Present at Upcoming Investor Conferences - GlobeNewswire
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business UpdateOn November 7, 2024, Vigil Neuroscience, Inc. (NASDAQ: VIGL) released its financial results for the third quarter ended September 30, 2024. The company, dedic - Defense World
Vigil Neuroscience’s (VIGL) “Buy” Rating Reiterated at HC Wainwright - Defense World
Vigil Neuroscience (NASDAQ:VIGL) Price Target Raised to $24.00 - Defense World
Finanzdaten der Vigil Neuroscience Inc-Aktie (VIGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):